Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
155 hedge funds and large institutions have $1.36B invested in Avadel Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 21 closing their positions.
188% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $10.9M
143% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 21
25% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 36
22% more funds holding
Funds holding: 127 → 155 (+28)
16% more capital invested
Capital invested by funds: $1.17B → $1.36B (+$182M)
0.1% less ownership
Funds ownership: 76.68% → 76.58% (-0.1%)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$77.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$60.2M |
| 3 |
TSC
Two Seas Capital
Rye,
New York
|
+$29.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$18M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$149M |
| 2 |
Millennium Management
New York
|
-$29.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.9M |
| 4 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$11.6M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$6.48M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
T. Rowe Price Associates
Baltimore,
Maryland
| – | +$479K | +29,391 | New |
|
AVDL Hedge Fund Activity: Q2 2024 in Review
155 of the 6,930 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2024, worth a combined $1.36B — up 16% from $1.17B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new AVDL positions and 21 closed out — a net gain of 30 holders — while 45 added to existing stakes and 36 trimmed.
The largest buyer was BlackRock, adding an estimated $77.3M. The largest seller was RTW Investments, exiting entirely with an estimated $149M sold.
- 155 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2024, up from 127 in Q1 2024.
- Funds reported $1.36B of Avadel Pharmaceuticals stock for Q2 2024, up 16% quarter-over-quarter.
- 51 funds opened new Avadel Pharmaceuticals positions in Q2 2024 and 21 closed out, a net change of +30 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $77.3M added.
- The largest Avadel Pharmaceuticals seller in Q2 2024 was RTW Investments, an estimated $149M sold.
Based on aggregated 13F filings for Q2 2024.